Investing in Power

Announcing our investment in Power’s Series A.

Megan Kao

February 21, 2024

Clinical trials are broken for patients, researchers, and biopharma sponsors. 

Every year, 86% of trials are delayed due to lack of enrollment, costing sponsors up to $8 million a day. Yet, less than 5% of U.S. patients partake in potentially life-changing trials. Patients wrestle with dense jargon, unclear tradeoffs, and an opaque, time-consuming enrollment process. One look at tells you all you need to know.

I witnessed this firsthand when my father was diagnosed with a rare form of leukemia. We nearly missed a critical trial, waiting weeks between hospital transfers and provider referrals. While we were lucky to find an academic hospital, many American patients must advocate for themselves. Only 36% of participants hear about a trial from their doctor. 

With increasing patient demand for self-help paired with archaic systems, we’ve seen a new model emerge to own the patient relationship and capture intent. This is why we are so excited to back Power

Power built a patient-led marketplace and recruitment management platform, flipping the traditional outbound model on its head. While there have been previous attempts to tackle patient recruitment, many were relegated to ad agency models without proper follow-through from research sites. With its network of high-intent patients, Power is able to access a more diverse patient base, encourage patients to share their electronic medical record (EMR), and ultimately deliver EMR qualified leads. This is a deceivingly simple step that saves time for both patients and researchers. Over 600,000 patients used Power to discover clinical trials last year. 

But most important to us was the Power team. When we met Brandon and Bask, we were struck by their ambition to solve a problem that hit close to home. Therapeutic options should be easily accessible to all patients — regardless of geographical location, ethnicity, or socioeconomic background. 

Today, we couldn’t be more thrilled to co-lead Power’s $12 million Series A, alongside our friends Nikhil Basu Trivedi at Footwork and Kin Ventures. 

Unlocking access for patients is only act one. We believe Power has the potential to redefine how patients, researchers, and life science partners interact in the clinical trial system.

Disclosure: Nothing presented within this article is intended to constitute legal, business, investment or tax advice, and under no circumstances should any information provided herein be used or considered as an offer to sell or a solicitation of an offer to buy an interest in any investment fund managed by Contrary LLC (“Contrary”) nor does such information constitute an offer to provide investment advisory services. Information provided reflects Contrary’s views as of a time, whereby such views are subject to change at any point and Contrary shall not be obligated to provide notice of any change. Companies mentioned in this article may be a representative sample of portfolio companies in which Contrary has invested in which the author believes such companies fit the objective criteria stated in commentary, which do not reflect all investments made by Contrary. No assumptions should be made that investments listed above were or will be profitable. Due to various risks and uncertainties, actual events, results or the actual experience may differ materially from those reflected or contemplated in these statements. Nothing contained in this article may be relied upon as a guarantee or assurance as to the future success of any particular company. Past performance is not indicative of future results. A list of investments made by Contrary (excluding investments for which the issuer has not provided permission for Contrary to disclose publicly, Fund of Fund investments and investments in which total invested capital is no more than $50,000) is available at

Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by Contrary. While taken from sources believed to be reliable, Contrary has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Please see for additional important information.